Physician profile
Steven C Ting
NPI 1740388578
$3,007.53
in general payments reported to CMS, 2019-2025
28 companies · $859 in 2025
The $859 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $202 · 2021: $539 · 2022: $422 · 2023: $268 · 2024: $316 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,314 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.76 |
| Education | $129.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $409.31 | 2020-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $331.35 | 2019-2025 | Farxiga |
| Travere Therapeutics, INC. | $323.30 | 2022-2025 | Filspari |
| Amgen INC. | $273.52 | 2022-2025 | Krystexxa, Tavneos |
| Alexion Pharmaceuticals, INC. | $182.18 | 2021-2025 | Ultomiris |
| Vifor Pharma, INC. | $150.07 | 2021-2025 | Veltassa, Korsuva |
| Allergan, INC. | $142.30 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $141.73 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $128.95 | 2021-2025 | Acthar |
| Calliditas Therapeutics US INC. | $126.82 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $119.95 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $115.32 | 2020-2024 | Rayaldee |
| Akebia Therapeutics INC | $111.83 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $57.40 | 2021 | |
| Daiichi Sankyo INC. | $40.85 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37.82 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.39 | 2024-2025 | Jardiance |
| Pharmacosmos Therapeutics INC. | $35.69 | 2023 | Monoferric |
| Fresenius USA Marketing, INC. | $33.92 | 2022-2023 | Korsuva, Velphoro |
| Horizon Therapeutics Plc | $33.91 | 2023 | Krystexxa |
| Ultragenyx Pharmaceutical INC. | $33.74 | 2019-2025 | Crysvita |
| Novartis Pharmaceuticals Corporation | $25.48 | 2025 | |
| Cormedix INC. | $25.39 | 2025 | Defencath |
| Chiesi USA, INC. | $24.12 | 2025 | Elfabrio |
| Novo Nordisk INC | $21.42 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $19.05 | 2020 | |
| Ardelyx, INC. | $13.75 | 2025 | Ibsrela |
| Cumberland Pharmaceuticals, INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.